more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$78.36 USD

+0.23 (0.29%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $78.35 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for AZN

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
BioPharmaceuticals: R&I: Symbicor...		2,362	2,538	2,728	2,721	2,495
BioPharmaceuticals: R&I: Pulmicor...		713	645	962	996	1,466
BioPharmaceuticals: R&I: Fasenra:...		1,553	1,396	1,258	949	704
BioPharmaceuticals: CVRM: Brilint...		1,324	1,358	1,472	1,593	1,581
BioPharmaceuticals: CVRM: Farxiga...		5,963	4,381	3,000	1,959	1,543
BioPharmaceuticals: R&I: Breztri:...		677	398	203	28	2
BioPharmaceuticals: CVRM: Lokelma...		412	289	175	76	14
Rare Disease: Koselugo: World [$M...		331	208	108	38	--
Oncology: World [$M]		17,145	14,631	13,048	10,850	8,667
BioPharmaceuticals: CVRM: World [...		10,585	9,188	8,020	7,096	--
BioPharmaceuticals: R&I: World [$...		6,107	5,765	6,034	5,357	--
BioPharmaceuticals: CVRM: roxadus...		--	0	174	30	--
BioPharmaceuticals: V&I: FluMist:...		216	175	253	--	--
Oncology: Others: World [$M]		224	44	50	--	--
BioPharmaceuticals: CVRM: Others:...		296	366	196	--	--
BioPharmaceuticals: R&I: Others: ...		324	421	594	--	--
Oncology: Enhertu: World [$M]		261	79	17	--	--
Oncology: Tagrisso: Emerging Mark...		1,621	1,567	--	--	--
Oncology: Imfinzi: Emerging Marke...		360	287	--	--	--
Oncology: Lynparza: Emerging Mark...		542	488	--	--	--
Oncology: Calquence: Emerging Mar...		98	45	--	--	--
Oncology: Enhertu: Emerging Marke...		169	51	--	--	--
Oncology: Orpathys: Emerging Mark...		44	33	--	--	--
Oncology: Zoladex: Emerging Marke...		687	657	--	--	--
Oncology: Others: Emerging Market...		165	27	--	--	--
Oncology: Emerging Markets Total ...		3,828	3,537	--	--	--
BioPharmaceuticals: CVRM: Farxiga...		2,211	1,665	--	--	--
BioPharmaceuticals: CVRM: Brilint...		285	286	--	--	--
BioPharmaceuticals: CVRM: Lokelma...		50	20	--	--	--
BioPharmaceuticals: CVRM: roxadus...		271	197	--	--	--
BioPharmaceuticals: CVRM: Crestor...		862	794	--	--	--
BioPharmaceuticals: CVRM: Seloken...		621	839	--	--	--
BioPharmaceuticals: CVRM: Others:...		152	194	--	--	--
BioPharmaceuticals: CVRM: Emergin...		4,586	4,119	--	--	--
BioPharmaceuticals: R&I: Symbicor...	--	753	608	--	--	--
BioPharmaceuticals: R&I: Fasenra:...	--	64	43	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	161	92	--	--	--
BioPharmaceuticals: R&I: Pulmicor...	--	575	462	--	--	--
BioPharmaceuticals: R&I: Others: ...	--	206	230	--	--	--
BioPharmaceuticals: R&I: Emerging...	--	1,771	1,443	--	--	--
BioPharmaceuticals: V&I: Synagis:...	--	195	173	--	--	--
BioPharmaceuticals: V&I: Emerging...	--	212	1,316	--	--	--
Rare Disease: Soliris: Emerging M...		424	301	--	--	--
Rare Disease: Ultomiris: Emerging...	--	71	38	--	--	--
Rare Disease: Strensiq: Emerging ...		40	35	--	--	--
Rare Disease: Koselugo: Emerging ...		59	26	--	--	--
Rare Disease: Kanuma: Emerging Ma...		29	31	--	--	--
Rare Disease: Emerging Markets [$...		623	431	--	--	--
Other Medicines: Nexium: Emerging...		578	568	--	--	--
Other Medicines: Others: Emerging...		153	220	--	--	--
Other Medicines: Emerging Markets...		731	788	--	--	--
Oncology: Tagrisso: Established R...		782	847	--	--	--
Oncology: Imfinzi: Established Ro...		802	401	--	--	--
Oncology: Lynparza: Established R...		281	269	--	--	--
Oncology: Calquence: Established ...		108	69	--	--	--
Oncology: Zoladex: Established Ro...		118	122	--	--	--
Oncology: Others: Established RoW...		47	10	--	--	--
Oncology: Established RoW [$M]		2,266	1,884	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		45	32	--	--	--
BioPharmaceuticals: CVRM: Establi...		744	684	--	--	--
BioPharmaceuticals: R&I: Symbicor...	--	334	375	--	--	--
BioPharmaceuticals: R&I: Fasenra:...	--	142	142	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	52	34	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	10	3	--	--	--
BioPharmaceuticals: R&I: Pulmicor...	--	42	49	--	--	--
BioPharmaceuticals: R&I: Others: ...	--	6	6	--	--	--
BioPharmaceuticals: R&I: Establis...	--	625	613	--	--	--
Oncology: Orpathys: World [$M]		44	33	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		182	150	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	280	116	--	--	--
BioPharmaceuticals: V&I: World [$...	--	1,012	4,736	--	--	--
BioPharmaceuticals: V&I: Establis...	--	295	1,225	--	--	--
BioPharmaceuticals: V&I: Synagis:...	--	177	191	--	--	--
Rare Disease: Soliris: World [$M]		3,145	3,762	--	--	--
Rare Disease: Soliris: Establishe...		317	476	--	--	--
Rare Disease: Ultomiris: Establis...	--	476	310	--	--	--
Rare Disease: Ultomiris: World [$...	--	2,965	1,965	--	--	--
Product Sales: Rare Disease: Stre...		1,152	958	--	--	--
Rare Disease: Strensiq: Establish...		86	76	--	--	--
Rare Disease: Koselugo: Establish...		24	0	--	--	--
Rare Disease: Kanuma: Established...		8	8	--	--	--
Rare Disease: Kanuma: World [$M]		171	160	--	--	--
Product Sales: Rare Disease: Worl...	--	7,764	7,053	--	--	--
Rare Disease: Established RoW [$M...		911	870	--	--	--
Other Medicines: Nexium: Establis...		199	551	--	--	--
Other Medicines: Others: Establis...		8	19	--	--	--
Other Medicines: Others: World [$...		231	340	--	--	--
Other Medicines: Established RoW ...		207	570	--	--	--
Other Medicines: World [$M]		1,176	1,625	--	--	--
Total Product Sales: Emerging Mar...	--	11,751	11,634	--	--	--
Collaboration Revenue: Total [$M]	--	594	1,353	--	--	--
Oncology: Tagrisso: World [$M]		5,799	5,444	5,015	4,328	3,189
Oncology: Imfinzi: World [$M]		4,237	2,784	2,412	2,042	1,469
Oncology: Lynparza: World [$M]		2,811	2,638	2,348	1,776	1,198
Oncology: Calquence: World [$M]		2,514	2,057	1,238	522	164
Oncology: Zoladex: World [$M]	--	952	927	948	888	813
BioPharmaceuticals: V&I: Synagis:...		546	578	410	372	358
Other medicines: Nexium: World [$...		945	1,285	1,326	1,492	1,483
BioPharmaceuticals: CVRM: Crestor...		1,107	1,048	1,096	1,180	1,278
BioPharmaceuticals: CVRM: Seloken...		640	862	951	821	760
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
BioPharmaceuticals: R&I: Symbicor...		726	973	1,065	1,022	829
BioPharmaceuticals: R&I: Pulmicor...		28	65	72	71	110
BioPharmaceuticals: CVRM: Crestor...		55	65	80	92	104
BioPharmaceuticals: CVRM: Seloken...		1	0	1	13	37
Oncology: Zoladex: U.S. [$M]		14	15	13	5	7
Oncology: Tagrisso: U.S. [$M]		2,276	2,007	1,780	1,566	1,268
Other Medicines: Nexium: U.S. [$M...		115	120	128	169	218
BioPharmaceuticals: R&I: Fasenra:...		992	906	790	603	482
BioPharmaceuticals: CVRM: Brilint...		744	744	735	732	710
Oncology: Lynparza: U.S. [$M]		1,254	1,226	1,087	876	626
Oncology: Imfinzi: U.S. [$M]		2,317	1,552	1,245	1,185	1,041
Oncology: Calquence: U.S. [$M]		1,815	1,657	1,089	511	162
BioPharmaceuticals: CVRM: Farxiga...		1,451	1,071	732	569	537
BioPharmaceuticals: CVRM: Lokelma...		214	170	115	57	13
Rare Disease: Koselugo: U.S. [$M]		195	162	104	38	--
Oncology: U.S. [$M]		7,719	6,484	5,359	4,250	3,449
BioPharmaceuticals: CVRM: U.S. [$...		2,752	2,479	2,124	2,083	--
BioPharmaceuticals: R&I: U.S. [$M...		2,547	2,655	2,404	1,941	--
Total Product Sales: Total World ...		43,789	42,998	36,541	25,890	23,565
Total Product Sales: U.S. Sales [...		17,961	17,254	12,000	8,638	7,747
BioPharmaceuticals: V&I: FluMist:...	--	23	21	27	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	260	111	--	--	--
Oncology: Europe [$M]		3,332	2,726	--	--	--
BioPharmaceuticals: CVRM: Farxiga...		1,881	1,297	--	--	--
BioPharmaceuticals: CVRM: Brilint...		271	282	--	--	--
BioPharmaceuticals: CVRM: Lokelma...		58	30	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		62	41	--	--	--
BioPharmaceuticals: CVRM: Crestor...		52	41	--	--	--
BioPharmaceuticals: CVRM: Seloken...		11	14	--	--	--
BioPharmaceuticals: CVRM: Others:...		109	128	--	--	--
BioPharmaceuticals: CVRM: Europe ...		2,503	1,906	--	--	--
BioPharmaceuticals: R&I: Symbicor...	--	549	582	--	--	--
BioPharmaceuticals: R&I: Fasenra:...	--	355	305	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	81	33	--	--	--
BioPharmaceuticals: R&I: Pulmicor...	--	68	69	--	--	--
BioPharmaceuticals: R&I: Others: ...	--	30	42	--	--	--
BioPharmaceuticals: R&I: Saphnelo...	--	8	2	--	--	--
BioPharmaceuticals: R&I: Europe [...	--	1,164	1,054	--	--	--
BioPharmaceuticals: V&I: Europe [...	--	396	1,027	--	--	--
BioPharmaceuticals: V&I: Synagis:...	--	175	213	--	--	--
BioPharmaceuticals: V&I: FluMist:...	--	188	151	--	--	--
Rare Disease: Soliris: Europe [$M...		670	805	--	--	--
Other Medicines: Nexium: Europe [...		53	46	--	--	--
Other Medicines: Others: Europe [...		52	77	--	--	--
Rare Disease: Europe [$M]		1,529	1,428	--	--	--
Other Medicines: Europe [$M]		105	123	--	--	--
BioPharmaceuticals: CVRM: Farxiga...		420	348	--	--	--
BioPharmaceuticals: CVRM: Brilint...	--	24	46	--	--	--
BioPharmaceuticals: CVRM: Lokelma...		90	69	--	--	--
BioPharmaceuticals: CVRM: Crestor...		138	148	--	--	--
BioPharmaceuticals: CVRM: Seloken...		7	9	--	--	--
BioPharmaceuticals: CVRM: Others:...		5	10	--	--	--
BioPharmaceuticals: CVRM: Andexxa...		75	77	--	--	--
BioPharmaceuticals: CVRM: Others:...		30	34	--	--	--
BioPharmaceuticals: R&I: Other: U...	--	82	143	--	--	--
BioPharmaceuticals: R&I: Breztri:...	--	383	239	--	--	--
Rare Disease: Soliris: U.S. [$M]		1,734	2,180	--	--	--
Rare Disease: Ultomiris: U.S. [$M...	--	1,750	1,136	--	--	--
Rare Disease: Strensiq: U.S. [$M]	--	937	769	--	--	--
Rare Disease: Kanuma: U.S. [$M]		85	77	--	--	--
Rare Disease: U.S. [$M]	--	4,701	4,324	--	--	--
Other Medicines: Others: U.S. [$M...		18	24	--	--	--
Other Medicines: U.S. [$M]		133	144	--	--	--
Rare Disease: Ultomiris: Europe [...	--	668	481	--	--	--
Rare Disease: Strensiq: Europe [$...		89	78	--	--	--
Rare Disease: Koselugo: Europe [$...		53	20	--	--	--
Rare Disease: Kanuma: Europe [$M]		49	44	--	--	--
Total Product Sales: Europe [$M]	--	9,029	8,264	--	--	--
Total Product Sales: Established ...	--	5,048	5,846	--	--	--
BioPharmaceuticals: V&I: FluMist:...	--	4	2	--	--	--
BioPharmaceuticals: V&I: U.S. [$M...	--	109	1,168	--	--	--
Oncology: Tagrisso: Europe [$M]		1,120	1,023	--	--	--
Oncology: Imfinzi: Europe [$M]		758	544	--	--	--
Oncology: Lynparza: Europe [$M]		734	655	--	--	--
Oncology: Calquence: Europe [$M]		493	286	--	--	--
Oncology: Enhertu: Europe [$M]		60	21	--	--	--
Oncology: Enhertu: Established Ro...		32	7	--	--	--
Oncology: Zoladex: Europe [$M]		133	133	--	--	--
Oncology: Others: Europe [$M]		6	6	--	--	--

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
BioPharmaceuticals: R&I: Symbicor...		769	520	555	600	688
BioPharmaceuticals: R&I: Pulmicor...		224	219	148	124	221
BioPharmaceuticals: R&I: Fasenra:...		358	420	389	406	338
BioPharmaceuticals: CVRM: Brilint...		323	329	331	331	334
BioPharmaceuticals: CVRM: Farxiga...		1,845	1,606	1,554	1,505	1,299
BioPharmaceuticals: R&I: Breztri:...		219	199	171	163	144
BioPharmaceuticals: CVRM: Lokelma...		114	112	102	100	98
Rare Disease: Koselugo: World [$M...		132	85	87	80	79
Oncology: World [$M]		4,760	4,453	4,389	4,382	3,920
BioPharmaceuticals: CVRM: World [...		3,012	2,698	2,683	2,675	2,530
BioPharmaceuticals: R&I: World [$...		1,804	1,590	1,451	1,483	1,583
BioPharmaceuticals: CVRM: roxadus...		75	--	--	--	--
BioPharmaceuticals: V&I: FluMist:...		7	138	75	0	2
Oncology: Others: World [$M]		107	50	54	54	66
BioPharmaceuticals: CVRM: Others:...		141	58	66	69	102
BioPharmaceuticals: R&I: Others: ...		98	80	67	71	106
Oncology: Enhertu: World [$M]		122	83	73	67	37
Oncology: Tagrisso: Emerging Mark...		488	360	409	408	444
Oncology: Imfinzi: Emerging Marke...		129	90	87	102	81
Oncology: Lynparza: Emerging Mark...		167	133	131	142	137
Oncology: Calquence: Emerging Mar...		39	29	28	24	18
Oncology: Enhertu: Emerging Marke...		83	48	48	48	24
Oncology: Orpathys: Emerging Mark...		12	11	12	13	8
Oncology: Zoladex: Emerging Marke...		214	167	182	171	167
Oncology: Others: Emerging Market...		66	38	42	36	50
Oncology: Emerging Markets Total ...		1,202	904	971	987	966
BioPharmaceuticals: CVRM: Farxiga...		711	559	579	576	498
BioPharmaceuticals: CVRM: Brilint...		88	61	64	79	82
BioPharmaceuticals: CVRM: Lokelma...		21	13	13	13	11
BioPharmaceuticals: CVRM: roxadus...		75	63	74	73	61
BioPharmaceuticals: CVRM: Crestor...		241	184	219	217	241
BioPharmaceuticals: CVRM: Seloken...		161	139	149	159	173
BioPharmaceuticals: CVRM: Others:...		67	28	29	34	61
BioPharmaceuticals: CVRM: Emergin...		1,365	1,078	1,161	1,182	1,165
BioPharmaceuticals: R&I: Symbicor...		253	153	195	177	229
BioPharmaceuticals: R&I: Fasenra:...		22	16	19	14	14
BioPharmaceuticals: R&I: Breztri:...		70	38	42	43	38
BioPharmaceuticals: R&I: Pulmicor...		191	183	119	90	182
BioPharmaceuticals: R&I: Others: ...		49	62	45	32	67
BioPharmaceuticals: R&I: Emerging...		588	456	422	360	533
BioPharmaceuticals: V&I: Synagis:...		90	37	32	49	78
BioPharmaceuticals: V&I: Emerging...		90	31	32	46	104
Rare Disease: Soliris: Emerging M...		125	86	124	99	115
Rare Disease: Ultomiris: Emerging...		32	24	17	17	13
Rare Disease: Strensiq: Emerging ...		21	11	5	9	15
Rare Disease: Koselugo: Emerging ...		59	10	11	14	24
Rare Disease: Kanuma: Emerging Ma...		14	5	6	11	6
Rare Disease: Emerging Markets [$...		251	136	163	150	173
Other Medicines: Nexium: Emerging...		172	120	153	149	156
Other Medicines: Others: Emerging...		34	31	37	36	49
Other Medicines: Emerging Markets...		206	151	190	185	205
Oncology: Tagrisso: Established R...		182	163	198	218	202
Oncology: Imfinzi: Established Ro...		170	225	221	222	134
Oncology: Lynparza: Established R...		59	65	71	77	68
Oncology: Calquence: Established ...		32	28	30	27	22
Oncology: Zoladex: Established Ro...		24	50	21	24	24
Oncology: Others: Established RoW...		30	10	10	15	13
Oncology: Established RoW [$M]		521	579	583	614	490
BioPharmaceuticals: CVRM: Andexxa...		8	17	5	14	9
BioPharmaceuticals: CVRM: Establi...		183	161	175	221	186
BioPharmaceuticals: R&I: Symbicor...		75	88	81	86	79
BioPharmaceuticals: R&I: Fasenra:...		33	36	35	36	35
BioPharmaceuticals: R&I: Breztri:...		14	15	12	15	10
BioPharmaceuticals: R&I: Saphnelo...		3	3	3	2	2
BioPharmaceuticals: R&I: Pulmicor...		8	12	11	11	9
BioPharmaceuticals: R&I: Others: ...		2	2	1	2	1
BioPharmaceuticals: R&I: Establis...		149	170	154	160	141
Oncology: Orpathys: World [$M]		12	11	12	13	8
BioPharmaceuticals: CVRM: Andexxa...		47	53	40	45	44
BioPharmaceuticals: R&I: Saphnelo...		91	89	76	68	47
BioPharmaceuticals: V&I: World [$...		212	345	224	88	355
BioPharmaceuticals: V&I: Establis...		21	60	55	27	153
BioPharmaceuticals: V&I: Synagis:...		21	60	51	28	38
Rare Disease: Soliris: World [$M]		739	715	781	814	834
Rare Disease: Soliris: Establishe...		61	68	74	86	88
Rare Disease: Ultomiris: Establis...		143	138	131	110	98
Rare Disease: Ultomiris: World [$...	--	859	825	777	713	651
Product Sales: Rare Disease: Stre...		313	305	285	300	262
Rare Disease: Strensiq: Establish...		22	22	21	22	21
Rare Disease: Koselugo: Establish...		9	9	7	6	3
Rare Disease: Kanuma: Established...		2	2	2	2	2
Rare Disease: Kanuma: World [$M]		53	41	44	46	40
Product Sales: Rare Disease: Worl...		2,096	1,971	1,974	1,953	1,866
Rare Disease: Established RoW [$M...		237	239	235	226	212
Other Medicines: Nexium: Establis...		33	46	51	55	47
Other Medicines: Others: Establis...		1	2	1	3	2
Other Medicines: Others: World [$...		53	57	53	53	68
Other Medicines: Established RoW ...		34	48	52	58	49
Other Medicines: World [$M]		293	266	297	301	312
Total Product Sales: Emerging Mar...	--	3,702	2,756	2,939	2,910	3,146
Collaboration Revenue: Total [$M]		45	277	97	193	27
Alliance Revenue: Total [$M]		457	424	377	341	286
Oncology: Tagrisso: World [$M]		1,595	1,419	1,465	1,491	1,424
Oncology: Imfinzi: World [$M]		1,113	1,135	1,126	1,076	900
Oncology: Lynparza: World [$M]		705	741	702	717	651
Oncology: Calquence: World [$M]		718	675	654	653	532
Oncology: Zoladex: World [$M]		276	254	239	233	227
BioPharmaceuticals: V&I: Synagis:...		171	164	99	87	198
Other medicines: Nexium: World [$...		240	209	244	248	244
BioPharmaceuticals: CVRM: Crestor...		297	247	275	280	305
BioPharmaceuticals: CVRM: Seloken...		165	144	153	164	179
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
BioPharmaceuticals: R&I: Symbicor...		299	137	156	200	233
BioPharmaceuticals: R&I: Pulmicor...		5	5	5	7	10
BioPharmaceuticals: CVRM: Crestor...		10	15	14	12	14
BioPharmaceuticals: CVRM: Seloken...	--	0	0	--	1	0
Oncology: Zoladex: U.S. [$M]		3	2	5	4	3
Oncology: Tagrisso: U.S. [$M]		623	597	577	581	521
Other Medicines: Nexium: U.S. [$M...		22	26	29	30	29
BioPharmaceuticals: R&I: Fasenra:...		210	275	249	267	201
BioPharmaceuticals: CVRM: Brilint...		163	194	193	178	179
Oncology: Lynparza: U.S. [$M]		288	352	322	311	268
Oncology: Imfinzi: U.S. [$M]		582	609	610	576	522
Oncology: Calquence: U.S. [$M]		494	478	468	485	384
BioPharmaceuticals: CVRM: Farxiga...		473	451	366	339	296
BioPharmaceuticals: CVRM: Lokelma...		52	58	51	49	56
Rare Disease: Koselugo: U.S. [$M]		46	51	54	48	41
Oncology: U.S. [$M]		2,084	2,067	1,986	1,962	1,704
BioPharmaceuticals: CVRM: U.S. [$...		748	780	690	661	622
BioPharmaceuticals: R&I: U.S. [$M...		737	647	609	674	617
Total Product Sales: Total World ...		12,177	11,323	11,018	10,882	10,566
Total Product Sales: U.S. Sales [...		4,827	4,814	4,515	4,525	4,073
BioPharmaceuticals: V&I: FluMist:...		2	7	15	0	0
BioPharmaceuticals: R&I: Saphnelo...		83	82	71	64	44
Oncology: Europe [$M]		953	903	849	819	760
BioPharmaceuticals: CVRM: Farxiga...		553	525	506	456	393
BioPharmaceuticals: CVRM: Brilint...		67	68	68	68	67
BioPharmaceuticals: CVRM: Lokelma...		18	17	16	14	11
BioPharmaceuticals: CVRM: Andexxa...		18	18	15	15	15
BioPharmaceuticals: CVRM: Crestor...		12	11	9	16	16
BioPharmaceuticals: CVRM: Seloken...	--	3	3	2	2	4
BioPharmaceuticals: CVRM: Others:...		45	22	27	25	35
BioPharmaceuticals: CVRM: Europe ...		716	679	657	611	557
BioPharmaceuticals: R&I: Symbicor...		142	142	123	137	147
BioPharmaceuticals: R&I: Fasenra:...		93	93	86	89	88
BioPharmaceuticals: R&I: Breztri:...		30	26	19	21	15
BioPharmaceuticals: R&I: Pulmicor...		20	19	13	16	20
BioPharmaceuticals: R&I: Others: ...		14	7	7	7	8
BioPharmaceuticals: R&I: Saphnelo...		4	3	2	1	1
BioPharmaceuticals: R&I: Europe [...		330	317	266	289	292
BioPharmaceuticals: V&I: Europe [...		74	195	122	15	98
BioPharmaceuticals: V&I: Synagis:...		61	67	16	10	82
BioPharmaceuticals: V&I: FluMist:...	--	5	130	56	0	2
Rare Disease: Soliris: Europe [$M...		142	140	163	184	183
Other Medicines: Nexium: Europe [...		13	17	11	14	12
Other Medicines: Others: Europe [...		16	21	8	12	10
Rare Disease: Europe [$M]		401	364	397	381	387
Other Medicines: Europe [$M]		29	38	19	26	22
BioPharmaceuticals: CVRM: Farxiga...		108	71	103	134	112
BioPharmaceuticals: CVRM: Brilint...		5	6	6	6	6
BioPharmaceuticals: CVRM: Lokelma...		23	24	22	24	20
BioPharmaceuticals: CVRM: Crestor...		34	37	33	35	34
BioPharmaceuticals: CVRM: Seloken...		1	2	2	2	2
BioPharmaceuticals: CVRM: Others:...		4	1	1	1	1
BioPharmaceuticals: CVRM: Andexxa...		20	18	20	16	20
BioPharmaceuticals: CVRM: Others:...		25	7	9	9	5
BioPharmaceuticals: R&I: Other: U...		28	9	14	30	30
BioPharmaceuticals: R&I: Breztri:...		105	120	98	84	81
Rare Disease: Soliris: U.S. [$M]		411	421	420	445	448
Rare Disease: Ultomiris: U.S. [$M...	--	482	490	445	434	381
Rare Disease: Strensiq: U.S. [$M]		246	247	237	248	205
Rare Disease: Kanuma: U.S. [$M]		22	23	23	21	19
Rare Disease: U.S. [$M]		1,207	1,232	1,179	1,196	1,094
Other Medicines: Others: U.S. [$M...		2	3	7	2	7
Other Medicines: U.S. [$M]		24	29	36	32	36
Rare Disease: Ultomiris: Europe [...		202	173	184	152	159
Rare Disease: Strensiq: Europe [$...		24	25	22	21	21
Rare Disease: Koselugo: Europe [$...		18	15	15	12	11
Rare Disease: Kanuma: Europe [$M]		15	11	13	12	13
Total Product Sales: Europe [$M]	--	2,503	2,496	2,310	2,141	2,116
Total Product Sales: Established ...	--	1,145	1,257	1,254	1,306	1,231
BioPharmaceuticals: V&I: FluMist:...	--	0	0	4	0	0
BioPharmaceuticals: V&I: U.S. [$M...		27	59	15	0	0
Oncology: Tagrisso: Europe [$M]		302	299	281	284	257
Oncology: Imfinzi: Europe [$M]		232	211	208	176	163
Oncology: Lynparza: Europe [$M]		191	191	178	187	178
Oncology: Calquence: Europe [$M]		153	140	128	117	108
Oncology: Enhertu: Europe [$M]		26	20	16	14	10
Oncology: Enhertu: Established Ro...		13	15	9	5	3
Oncology: Zoladex: Europe [$M]		35	35	31	34	33
Oncology: Others: Europe [$M]		6	1	1	1	1

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators